Delivery Order SPE2DB22D3301-SPE2DB26FX3HQ
Award Date 10/14/25
Potential Completion Date 10/15/25
Potential Value $8.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. The order, valued at $4,710.99 with a completion date of September 10, 2025, represents a firm fixed price contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor that serves military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $22,056.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply procurement executed under a non-set-aside vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- AmerisourceBergen Drug Corp received a competitively awarded delivery order from the Defense Logistics Agency (DLA) on August 26, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $142,793.60. The contract was awarded under firm fixed-price terms with an ultimate completion date of August 27, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with a ceiling value of $110,915.56 under a firm fixed price contract type. This delivery order, which is not set-aside and was competitively awarded, represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. HEPLISAV-B is a hepatitis B vaccine, and this procurement...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,527.44 delivery order on September 19, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, non-set-aside contract with a completion date of September 22, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $1,684.96. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor agreement running through December 2026. The product will be delivered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $8,424.80 with a firm fixed price structure. The contract, which is not set-aside and was competitively awarded, carries an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $3,228.20 with a completion date of August 29, 2025. This delivery order represents a firm fixed-price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 mL syringes valued at $2,106.20. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 27, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...